Study on core genes and potential immunological and metabolic mechanisms associated with Tongmai yangxin pills in the treatment of coronary heart disease
- VernacularTitle:通脉养心丸治疗冠心病的核心基因及其潜在免疫和代谢机制
- Author:
Junchi GUO
1
;
Mingyan ZHANG
2
;
Yingqiang ZHAO
3
;
Meijuan LU
3
Author Information
1. School of Graduate，Tianjin University of Traditional Chinese Medicine，Tianjin 301617，China
2. Evidence-based Medicine Center，Tianjin University of Traditional Chinese Medicine，Tianjin 301617，China
3. Dept. of Cardiology，the Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine，Tianjin 300250，China
- Publication Type:Journal Article
- Keywords:
Tongmai yangxin pills;
Mendelian randomization;
coronary heart disease;
protein quantitative trait loci;
core
- From:
China Pharmacy
2025;36(17):2148-2153
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To identify core genes associated with the treatment of coronary heart disease （CHD） with Tongmai yangxin pills， and predict their potential immunological and metabolic mechanisms. METHODS Mendelian randomization （MR） analysis was conducted using protein quantitative trait loci （pQTL） data from the UK Biobank and Icelandic，and data from genome- wide association study to screen core genes related to Tongmai yangxin pills in the treatment of CHD. Gene expression changes were further validated using transcriptomic sequencing data. Mediation analyses of immune cells and plasma metabolites were subsequently performed to explore the downstream regulatory networks of these core genes. RESULTS A total of 62 positive pQTL genes showed significant causal associations with CHD. MR analysis combined with transcriptomic sequencing validation identified three core genes FAM3D，OXT， and ENPP5-associated with Tongmai yangxin pills in the treatment of CHD. The transcriptomic sequencing results showed that after treatment with Tongmai yangxin pills， the expression levels of FAM3D and OXT were significantly reduced （P＜0.01）， while the expression level of ENPP5 was significantly increased （P＜0.05）. Mediation analyses between immune cells and plasma metabolites indicated that these genes may positively or negatively regulate CHD through immune pathways involving regulatory T cells and myeloid dendritic cells expressing CD11c and CD62L， as well as through metabolic pathways related to lipid and fatty acid metabolism， cholesterol metabolism， and bile acid metabolism. CONCLUSIONS This study identified FAM3D，OXT， and ENPP5 as core genes associated with the treatment of CHD by Tongmai yangxin pills， which may exert therapeutic effects via modulation of immune cells and plasma metabolic pathways involving fatty acids and bile acids.
